From With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?:

Jeff Tong

Jeff Tong—

Jeff Tong is the CEO of Ambys Medicines and a venture partner at Third Rock Ventures. Photo courtesy of Tri Nguyen/Ambys Medicines

Underwriters and Partners

Xconomy Insight

Sponsored · Whitepaper
How Healthy Are Your Market Access Programs?
A Guide to Performing Check-ups on Pharmaceutical Distribution & Patient Access Programs
Archbow Consulting

Sponsored · Webinar
Nov. 12 – High-Throughput Assessment of Compound-Induced Cardiotoxicity Using Human iPSC-Derived Cardiomyocytes
Provide an in vitro drug-induced proarrhythmia assessment & strengthen pharmacological safety profiles of drug candidates
Eurofins DiscoverX

Xconomy Insight · Special Report
Biotech Startups: How to Succeed in a COVID-19 World
Industry experts explain what it takes to launch a new biotech company

Xconomy on Demand

We offer a number of ways to subscribe for free!